Loading...
Immune checkpoint inhibitors combined with other targeted agents are under active investigation as treatments for gastric cancer, based on promising data and regulatory approval for combinations used in patients with hepatocellular cancer (HCC) and uterine cancer.
Investigators in Japan now report the results of an industry-sponsored, single-arm, open-label, phase II trial (EPOC1706), in which 29 patients with metastatic gastric cancer received the immune checkpoint inhibitor pembrolizumab combined with the tyrosine kinase inhibitor lenvatinib, which targets vascular endothelial growth factor (VEGF) and other pathways. Patients with ≤1 prior chemotherapy regimen were treated with pembrolizumab (200 mg every 3 weeks) plus oral lenvatinib (20 …